



Corres. and Mail  
**BOX AF**

**RECEIVED**

AUG 05 2002

**TECH CENTER 1600/2900**

**RESPONSE AFTER FINAL  
EXPEDITED PROCESSING  
BOX AF**

AF-  
1642

<b>IN THE UNITED STATES PATENT AND TRADEMARK OFFICE</b>	<i>Application Number</i>	09/434,382
	<i>Filing Date</i>	5 November 1999
	<i>First Named Inventor</i>	Sean V. TAVTIGIAN
	<i>Group Art Unit</i>	1642
	<i>Examiner Name</i>	J.E. Hunt
	<i>Attorney Docket Number</i>	2318-247
<i>Title of the Invention:</i> <b>CHROMOSOME 17p-LINKED PROSTATE CANCER SUSCEPTIBILITY GENE</b>		

**AMENDMENT AFTER FINAL**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Further to the Response After Final filed on 2 April 2002 and in view of the Advisory Action mailed on 18 June 2002, please amend the above-identified application as follows.

#  
16/B<sup>us</sup>  
~~160~~  
~~8-2-02~~  
Jm  
3/19/03

IN THE CLAIMS:

Please cancel claims 16-24 and 27-60 without prejudice to filing one or more divisional applications.

Please cancel claims 10, 25, 64-66 and 78 without prejudice to filing a continuation application.

**REMARKS**

Claims 10, 25, 64-66 and 78, the sole rejected claims, have been canceled, as well as the non-elected claims 16-24 and 27-60. Thus, it is believed that the application is now in condition for allowance in view of the Examiner's indication that claims 1-3, 11-15, 61-63 and 67-77 are allowable. Reconsideration of the application and early notice of allowance are requested. The